Engage with experts and peers on all aspects of cardiac catheterization.
Richard A. Lange, MD, MBA and L. David Hillis, MD
In FAME II, a prospective study conducted at 28 centers in Europe and the United States, >1200 patients with ischemia (as determined by fractional flow reserve [FFR]) were randomly assigned to receive (a) PCI (with a DES) and optimal medical therapy (OMT) or (b) OMT alone. The primary endpoint was a composite of death, myocardial infarction…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: FAME II, FFR, optimal medical therapy, PCI
-
0 Recommendations
- |
-
5 Comments
Richard A. Lange, MD, MBA and L. David Hillis, MD
A study of data from FRANCE 2, a prospectively maintained, multicenter registry of the French national experience with transcatheter aortic valve implantation (TAVI), has now been published in the New England Journal of Medicine. The registry captured every TAVI performed at all 34 active centers in France and Monaco; it therefore reflects “real-life” experience with TAVI in patients with…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Tags: aortic stenosis, aortic valve replacement, CoreValve, FDA, FRANCE 2, PARTNER, Sapien, TAVI
-
0 Recommendations
- |
-
4 Comments
